C07K 2317/56
Variable region, i.e. vh and/or vl
Official title: variable (Fv) region, i.e. VH and/or VL
C07K2317/56 (Variable region, i.e. vh and/or vl) appears on 12,087 US grants and 22,979 published applications in this corpus.
Search patents in C07K- Granted patents
- 12,087
- Published applications
- 22,979
- Assignees
- 4,430
- Inventors
- 29,055
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 8 | 0 |
| 1997 | 13 | 0 |
| 1998 | 17 | 0 |
| 1999 | 33 | 0 |
| 2000 | 18 | 0 |
| 2001 | 32 | 5 |
| 2002 | 32 | 48 |
| 2003 | 25 | 162 |
| 2004 | 32 | 182 |
| 2005 | 34 | 235 |
| 2006 | 58 | 266 |
| 2007 | 81 | 237 |
| 2008 | 121 | 315 |
| 2009 | 148 | 531 |
| 2010 | 245 | 565 |
| 2011 | 296 | 677 |
| 2012 | 376 | 647 |
| 2013 | 461 | 718 |
| 2014 | 451 | 838 |
| 2015 | 564 | 954 |
| 2016 | 671 | 1177 |
| 2017 | 721 | 1271 |
| 2018 | 760 | 1246 |
| 2019 | 835 | 1260 |
| 2020 | 901 | 1503 |
| 2021 | 868 | 1671 |
| 2022 | 836 | 1636 |
| 2023 | 765 | 1769 |
| 2024 | 957 | 1934 |
| 2025 | 1008 | 1729 |
| 2026 | 719 | 1403 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Enhancement of immune response with oral immunoglobulin polypeptides6 Oct 2026US 12,752,004 B2Iogenetics, LLC
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- Aggrecan binding immunoglobulins6 Oct 2026US 12,753,224 B2Ablynx N. V.
- Compositions and methods for genetically-encoded high voltage-activated calcium channel blockers using engineered ubiquitin ligases6 Oct 2026US 12,753,228 B2The Trustees of Columbia University in the City of New York
- Compositions and methods for modulating FLRT3 mediated signal transduction6 Oct 2026US 12,753,229 B2Nextcure, Inc.
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Targeted engineered interferon and uses thereof8 Oct 2026US 2026/0308221 A1Orionis Biosciences BV
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996